Galantamine-based hybrid molecules with acetylcholinesterase, butyrylcholinesterase and γ-secretase inhibition activities

Current Alzheimer Research

Volumn 9, Issue 5, 2012, Pages 600-605

  Vezenkov, L ^a   Sevalle, J ^b   Danalev, D ^a   Ivanov, T ^a   Bakalova, A ^c   Georgieva, M ^d   Checler, F ^b  

^a UNIVERSITY OF CHEMICAL TECHNOLOGY AND METALLURGY   (Bulgaria)

^b INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^c AGROBIOINSTITUTE   (Bulgaria)

^d Sopharma Pharmaceuticals   (Bulgaria)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Butyrylcholinesterase; Galantamine; Inhibitors; L Ala OH; N (3, 4 dichlorophenyl) D; Peptides; secretase

Indexed keywords

11 N DEMETHYL 11 N N [N (3,4 DICHLOROPHENYL) ALA] PHE GALANTAMINE; 11 N DEMETHYL 11 N N [N (3,4 DICHLOROPHENYL) ALA] VAL GALANTAMINE; 6 O N [N (3,4 DICHLORO PHENYL) ALA] LEU GLY GALANTAMINE; 6 O N [N (3,4 DICHLOROPHENYL) ALA] GLY GALANTAMINE; 6 O N [N (3,4 DICHLOROPHENYL) ALA] PHE GLY GALANTAMINE; 6 O N [N (3,4 DICHLOROPHENYL) ALA] VAL GLY GALANTAMINE; ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE DERIVATIVE; GAMMA SECRETASE; PLANT MEDICINAL PRODUCT; RIVASTIGMINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CELL STRAIN HEK293; CHOLINESTERASE INHIBITION; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; EMBRYO; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IC 50; IN VITRO STUDY; PRIORITY JOURNAL;

EID: 84861149200     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720512800618044     Document Type: Article

References (24)

1. Gauthier S, Gelinas I, Gauthier L. Functional disability in Alzheimer's disease. Int Psychogenriatr 9: 163-165 (1997).
2. Goate A, Ashall F. The genetics of Alzheimer's disease and mutations in amyloid β-protein precursor gene. In "Pathobiology of Alzheimer's disease", (Eds: Jenner P), Academic Press, San Diego, p.59-75 (1995).
3. Giacobini E. Butyrylcholinesterase: its role in brain function. In "Butyrylcholinesterase: its function and inhibitors" (Eds: Giocobini E), Martin Dunitz Ltd, London, p. 1-20 (2003).
4. Giacobini E. Cholinesterases and Cholinesterase Inhibitors. In 'Cholinesterase inhibitors: from the Calabar bean to Alzheimer therapy' (Eds: Giocobini E), Martin Dunitz Ltd, London, p.181-226 (2000).
5. Weinstock M. Selectivity of cholinesterase inhibition. CNS Drugs 12: 307-323 (1999).
6. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 12: 383-388 (1991).
7. Suh Y-H, Checler F. Amyloid precursor protein, presenilins and α- synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharm Rev 54: 469-525 (2002).
8. Checler, F. The multiple paradoxes of presenilins. J Neurochem 6: 1621-1627 (2001)
9. Checler, F. Presenilins: multifunctional proteins involved in Alzheimer's disease pathology. Iubmb Life 48: 33-39 (1999).
10. Wolfe M. γ-secretase inhibitors as molecular probes of presenilin function. J Mol Neurosci 17: 199-204 (2001).
11. Vezenkov LT, Georgieva M, Danalev DD, Ivanov Tch, Ivanova G, Synthesis and characterization of new galantamine derivatives comprising peptide moiety. Protein & Peptide Lett 16: 1024-1028 (2009).
12. Rakonczay Z. Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain. Acta Biol Hungarica 54: 183-189 (2003).
13. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor gene with familial Alzheimer's disease. Nature 349: 704-706 (1991).
14. Sevalle J, Amoyel A, Robert P, Fournié-Zaluski M, Roques B, Checler F. Aminopeptidase A contributes to the N-terminal truncation of amyloid beta-peptide. J Neurochem 109: 248-253 (2009).
15. Nizri E, Wirguin I, Brenner T. The role of cholinergic balance perturbation in neurological diseases. Drug News Perspect 20:421-429 (2007).
16. Pepeu G, Giovannini MG. Cholinesterase inhibitors and beyond. Curr Alzheimer Res 6: 86-96 (2009).
17. Holzgrabe U, Kapková P, Alptüzün V, Scheiber J, Kugelmann E. Targeting acetylcholinesterase to treat neurodegeneration. Expert Opin Ther Targets 11:161-79 (2007).
18. Savini L, Gaeta A, Fattorusso C, Catalanotti B, Campiani G, Chiasserini L, et al. Specific targeting of acetylcholinesterase and butyrylcholinesterase recognition sites. J Med Chem 46: 1-4 (2003).
19. Sussman JL, Harel M, Frolow F, Oefner C, Goldman A, Toker L, et al. Atomic Structure of acetylcholinesterase from Torpedo californica a prototypic acetylcholine-binding protein. Science 253: 872-879 (1991).
20. Luo W, Yu Q, Kulkarni S, Parrish D, Lahiri D, Brossi A and Greig N. Inhibition of human Acetyl and Butyrylcholinesterase by novel carbamates of (-) and (+) tetrahydrofurobenzofuran and methanobenzodioxepine. J Med Chem 49: 2174-2185 (2006).
21. Eyer P, Worek F, Kiderlen D, Sinko G, Stuglin A, Simeon-Rudolf V, et al. Molar absorption coefficients for the reduced Ellman reagent: reassessment. Anal Biochem 312: 224-227 (2003).
22. Pardossi-Piquard R, Petit A, Kawarai T, Sunyach C, Alves da Costa C, Vincent B, et al. Presenilin-dependent transcriptional control of the Aβ degrading enzyme neprilysin by intracellular domains of βAPP and APLP. Neuron 46: 541-554 (2005).
23. Barelli H, Lebeau A, Vizzavona J, Delaere P, Chevallier N, Drouot C, et al. Characterization of new polyclonal antibodies specific for 40 and 42 amino acid-long amyloid beta peptides: their use to examine the cell biology of presenilins and the immunohistochemistry of sporadic Alzheimer's disease and cerebral amyloid angiopathy cases. Mol Med 3: 695-707 (1997).
24. Chevallier N, Jiracek J, Vincent B, Baur CP, Spillantini MG, Goedert M, et al. Examination of the role of endopeptidase 3.4.24.15 in Aγ secretion by human transfected cells. Brit J Pharmacol 121: 556-562 (1997).